Migraine is one of the most common and most disabling disorders. Between attacks, migraine patients are otherwise normal but are sensitized to nonnoxious events known as triggers. The purpose of these studies was to investigate whether a headache-like event causes sensitization, or priming, to subsequent subthreshold events. Interleukin-6 (IL-6) was applied to the rat cranial dura mater which produced cutaneous facial and hind paw allodynia that lasted 24 hours. At 72 hours, IL-6-treated rats developed allodynia in response to dural stimulation with either a pH 6.8 or pH 7.0 solution and to a systemic nitric oxide (NO) donor, a well-known migraine trigger. Vehicle-treated rats did not respond to either pH stimulus or to the NO donor, demonstrating that IL-6 exposure primes rats to subthreshold stimuli. Inhibitors of brain-derived neurotrophic factor (BDNF) signaling given either systemically or intracisternally 24 hours after IL-6 eliminated responses to dural pH stimulation at 72 hours. Additionally, intracisternal administration of BDNF without previous dural stimulation produced allodynia and once resolved, animals were primed to dural pH 6.8/pH 7.0 and a systemic NO donor. Finally, hind paw IL-6 produced paw allodynia but not priming to paw injection of pH 7.0 at 72 hours demonstrating differences in priming depending on location. These data indicate that afferent input from the meninges produces BDNF-dependent priming of the dural nociceptive system. This primed state mimics the interictal period of migraine where attacks can be triggered by normally nonnoxious events and suggests that BDNF-dependent plasticity may contribute to migraine.
Introduction
Migraine is the third most common and eighth most disabling disease worldwide, 53 but the underlying pathophysiology is poorly understood. Biomarkers for migraine do not yet exist, and few changes can be found in patients who potentially explain the disorder. Although structural changes in the brain have been identified, 26 it is not clear whether these changes contribute to or whether they are a consequence of migraine. Migraine is often triggered by stimuli such as stress, skipping meals, foods/scents, excess/inadequate sleep, and changes in hormone levels. 1, 38, 46 However, these stimuli are innocuous in nonmigraineurs, suggesting that changes in the nervous system of migraine patients enhance their susceptibility to triggers. The location and mechanism of these changes are not well understood.
The frequency of migraine attacks can increase over time. Episodic migraine (0-14 migraine d/mo) can progress to chronic migraine (15 or more d/mo) at a rate of 2.5% per year, 9 although a transition from chronic to episodic migraine can also occur, 31 and higher frequency is associated with higher risk of progression. 29, 47 Another risk factor for progression is adequacy of treatment of acute migraines. When maximum treatment efficacy of acute attacks was achieved, the progression to chronic migraine was 1.9%, whereas progression increased to 2.7%, 4.4%, and 6.8% with moderate, poor, and very poor treatment efficacy, respectively. 30 These data indicate that migraine attacks and the severity of attacks can increase the likelihood of future migraines. Although mechanisms contributing to progression of migraine are not known, plasticity within the nervous system due to events occurring during attacks may play a role. 7 Several animal behavioral models have been developed that allow investigation of potential mechanisms contributing to headache disorders. Acute stimulation of the dura mater of rats produces behavioral responses consistent with headache, including generalized allodynia and decreased rearing. 19, 22, 23, 55 Repetitive dural stimulation promotes increased responses over time and animals eventually transition into chronic cutaneous allodynia 36 that is dependent on neuronal sensitization in the trigeminal nucleus caudalis (TNC). 13 Repetitive administration of sumatriptan to rats 20 or nitric oxide (NO) donors to mice 41 also sensitizes these animals to migraine triggers, even well after drug administration has ceased. Although these behavioral models cause sensitization to migraine triggers and mimic migraine progression, the underlying mechanisms have not been fully uncovered.
Previously, we showed that interleukin-6 (IL-6) administration to the rat dura produced cutaneous allodynia. 57 Although has been implicated in other pain conditions, elevated levels of IL-6 are present in migraine patients 45, 54 and a recent study found elevated IL-6 RNA in the cranial periosteum of chronic migraine patients. 39 Interleukin-6 administration to other tissues produces a state of hyperalgesic priming where, after resolution of IL-6 allodynia, animals display enhanced responses to nonnoxious or mildly noxious stimuli. 32, 42 The purpose of these studies was to determine whether meningeal IL-6 administration primes the dural afferent system to later subthreshold stimuli and to investigate the potential mechanisms by which this state of sensitization is mediated.
Methods

Animals
Adult male and female Sprague-Dawley rats (250-300 g, Harlan) were kept in a temperature-controlled room on a 12-hour light/dark cycle with food and water ad libitum. All procedures were performed in accordance with the policies of the IASP and the NIH guidelines for use of laboratory animals. The Institutional Animal Care and Use Committee (IACUC) of both The University of Arizona and The University of Texas at Dallas approved all procedures.
Surgeries
As previously described, 22, 56 dura cannulation surgeries were performed on rats (250-300) g. Animals were anesthetized with a combination of ketamine and xylazine (80 mg/kg and 12 mg/ kg), and an incision exposing the skull was made to the top of the skull. Once the skull was exposed, a 1-mm hole was made in the skull to expose the dura (1 mm left of midline, 1 mm anterior to lambda). A 1-mm guide cannula (Plastics One) was then inserted into the hole and secured with Vetbond (3M). Two screws (small parts) were placed rostral to the cannula biparietal to sagittal suture and posterior to bregma. Dental acrylic was used to secure the cannula to both the screws and the skull. A dummy cannula (Plastics One) was placed into the cannula to ensure patency. Animals received gentamicin (8 mg/kg) to minimize infection after surgery. Rats were housed separately and allowed 6 to 8 days for recovery before behavioral testing.
Behavioral testing
The animals were habituated in the testing chambers for a minimum of 1 hour before baseline. Animal weights were recorded and dural injections were given postbaseline. Testing of both facial and hind paw allodynia was conducted every hour for 5 hours using calibrated von Frey filaments thresholds which were determined by the "up-down" method. 6 The von Frey filaments were applied to the periorbital region of the face or to the plantar surface of the hind paw perpendicularly until the entire force was applied, and held for approximately 5 seconds or until animals withdrew. Maximum filaments used were 8 g for the periorbital region and 15 g for the hind paw. On completion of allodynia testing, all animals' cannula patency was verified by ink injection into the cannula and dissection post-mortem. The experimenter collecting measurements was blinded to the experimental conditions.
Intracisternal administration
Curved 25-gauge needles 1.5 inches long (BD Needles) were bent at approximately 40˚to no more than 45˚at a distance 7 mm from the bevel of the tip. These needles were then used, 1 per animal, while attached to a 25 mL microsyringe (Hamilton Syringes). Intracisternal injections were performed under light, isoflurane anesthesia administered through nose cone from a vaporizer. Animals were anesthetized for ,2 minutes. Animal heads were tilted forward to allow for exposure of the cisterna magna to perform injections. The curved needle was then positioned at the back of the neck just below the occiput and above the C1 vertebrae. The needle was inserted through the cisterna magna at the midline. Central placement of the needle was verified by drawing cerebrospinal fluid back into the needle before infusion of a given solution. Injections of 10 mL volume are made over a 10-second period after which the needle is removed. Animals recover from anesthesia for 5 minutes before being returned to cages or testing chambers. 18 
Rotarod
Animals were tested for motor impairments after intracisternal injection by their ability to balance and walk on a slowly rotating rod (Rotamex 4/8, 6.5 cm diameter for rats, respectively; rate of rotation, 10 revolutions per min, Columbus Instruments, Columbus, OH). Animals were trained for 3 consecutive days before Figure 1 . Dural application of interleukin-6 (IL-6) produces headacherelated behaviors. Withdrawal thresholds to tactile stimuli applied to the face (A) and hind paws (B) were measured in animals before and after dural application of 0.1 ng IL-6 (n 5 39) or Vehicle (pH 7.4) (n 5 28). Administration of IL-6 produced significant allodynia that lasted 24 hours in both face and hind paws. Two-factor analysis of variance indicated a significant effect of both treatment and time of both the face and hind paws. Significant differences among mean values for each group were determined by analysis of variance followed by Bonferroni post hoc test. challenge with a maximal cut-off time of 180 seconds. 8 Training consisted of a habituation to the rod while stationary for 180 seconds, as well as while rotating for a maximum of 180 seconds. Animals unable to stay on the rod for the full training period were excluded. On the fourth day, the length of time that animals were able to stay on the rotating rod during a 10-minute period was recorded as a baseline. Compounds were then administered through intracisternal injections and rats were assessed for time spent on the rod at peak behavioral response times (for allodynia) for the compound (3 hours postinjection) and no changes were observed (data not shown). Vehicle-treated rats were also tested for time spent on the rod.
Solution preparation
Rat recombinant IL-6 (R&D Systems) stock solution (10 mg/mL) was prepared in sterile 0.1% bovine serum albumin and diluted to final concentrations of 10 ng/mL in synthetic interstitial fluid (SIF) (pH 7.4, 310 Osmolality). Human recombinant BDNF and TrkB/ Fc (R&D Systems) were made into stock solutions (50 ng/mL and 25 ug/mL, respectively). The BDNF stock solution was made in sterile phosphate-buffered saline containing 0.1% bovine serum albumin, and TrkB/Fc stock solution was made in sterile phosphate-buffered saline. Both BDNF and TrkB/Fc were dissolved in artificial cerebrospinal fluid for intracisternal administration. Vehicle control was artificial cerebrospinal fluid. ANA-12 (Maybridge) was diluted to final concentration of 0.5 mg/kg in 10% polyethyl glycol 300 (PEG 300) and administered through intraperitoneal injection. APETx2 (Alomone Labs) was diluted in SIF solution at pH 6.8 to a final concentration of 20 mM/mL.
Data analysis
All behavioral data are graphed as mean 6 SEM. Statistical evaluations of allodynia studies were conducted using GraphPad Prism Version 6.0 (GraphPad Software Inc, La Jolla, CA). Data were analyzed among groups and across time by 1-or 2-way analysis of variance for treatment and time followed by Bonferroni posttest where appropriate. Data were also converted to area over the time-effect curve to allow for analysis of multiple treatment groups and analyzed with a 1-factor analysis of variance and Bonferroni posttest. In experiments where differences in allodynia at the 72-hour time point and 3 hours following this time point are being compared, t tests were used. Significance was set at P , 0.05 for all data analyses.
Results
We have shown previously that application of IL-6 to the rat dura mater produced cutaneous facial and hind paw allodynia that remained significantly different from baseline at 24 hours postinjection. 57 Interleukin-6 was applied in these studies to determine the duration of the allodynic response. Dural application of IL-6 (0.1 ng) produced both facial and hind paw allodynia that resolved by 48 hours after application ( Fig. 1 ) and remained at baseline at 72 hours. To ensure that the responses Figure 2 . Dural application of interleukin-6 (IL-6) primes animals to subthreshold stimuli. Animals that received a previous application of IL-6 exhibit cutaneous allodynia when dural pH 6.8 (A, n 5 9 for all groups) or pH 7.0 (B, n 5 10 for all groups) is applied after the resolution of allodynia at 72 hours. Withdrawal thresholds to tactile stimuli applied to the face (A and B) were measured in animals after application of dural pH 6.8 or pH 7.0, 72 hours after IL-6. Significant differences among mean values for each group were determined by analysis of variance followed by Bonferroni post hoc test. Increasing the pH value to pH 7.2 did not produce significant facial allodynia in either IL-6-treated rats or vehicle-treated rats (C). Acid-sensing ion channel 3 blocker APETx2 was able to attenuate facial (C) and hind paw (D) allodynia when administered with pH 6.8 at 72 hours after IL-6. Stimulation of the dura with Vehicle at 72 hours after IL-6 did not produce facial allodynia (C). Significant (**P , 0.01) differences among change of mean values at 72 hours for each group were determined using a t test (C and D). to dural IL-6 are due to initiation of afferent activity at the site of injection on the dura, the local anesthetic bupivacaine (0.5% wt/vol) was administered with IL-6 (0.1 ng) in the same injection. In the presence of dural bupivacaine, no allodynia of the facial or hind paw region was observed at any time point after IL-6 injection (Supplementary Figure 1 , available at http:// links.lww.com/PAIN/A332).
At the 72-hour time point, when animals had remained at baseline for 24 hours, they were tested for responses to pH 6.8 and pH 7.0 application to the dura mater. Previously, pH 6.8 was shown to not produce significant facial and hind paw allodynia, 58 indicating that this pH value is subthreshold in normal animals. At 72 hours after IL-6, stimulation of the dura with the normally subthreshold pH values of pH 6.8 or pH 7.0 produced robust facial and hind paw allodynia at 3 hours after administration (Fig. 2) . Only animals that had previously received IL-6, but not vehicle-treated animals (vehicle is pH 7.4 SIF), responded to the subsequent low pH stimulus. Higher pH values (pH 7.2) did not produce significant facial allodynia in either IL-6-treated rats or vehicle-treated rats (Fig. 2C) . To determine whether acid-sensing ion channels (ASICs) contribute to the behavioral response to low pH after sensitization (as we have shown previously in the absence of sensitization 56, 58 ), the ASIC3 blocker APETx2 was given with pH 6.8 at the 72-hour time point after IL-6. In the presence of APETx2, pH 6.8 did not produce significant facial allodynia indicating that ASICs still detect the decrease in pH even after sensitization with IL-6. Additionally, stimulation of the dura with pH 7.4 at the 72-hour time point after IL-6 did not produce facial allodynia, indicating that the animals are not simply responding to the pressure of the injection but that they are responding to decreased pH.
To determine whether IL-6 primes the dural afferent system only to subthreshold pH stimulation or whether they are sensitive to other stimuli, primed rats were given sodium nitroprusside (SNP, 3 mg/kg) at 72 hours after IL-6. Nitrous oxide donors are consistent migraine triggers in humans susceptible to migraine, but they do not trigger attacks in nonmigraine patients, 35 suggesting that sensitivity to these stimuli contributes to the pathophysiology of the disorder. This dose of SNP was chosen as it has been shown to be below threshold in normal rats. 20 In rats treated with dural IL-6, systemic SNP produced allodynia when given 72 hours later, whereas animals treated with dural vehicle did not respond to SNP (Fig. 3 ). These data demonstrate that dural stimulation with IL-6 produces changes in the nervous system that prime animals to normally subthreshold stimuli including common triggers of migraine.
Previous studies have shown that IL-6 injection into the mouse hind paw primes animals to a subsequent injection of subthreshold prostaglandin E 2 and that the primed state is dependent on brain-derived neurotrophic factor (BDNF) in the spinal cord. 32 To test whether priming in the context of headache is dependent on BDNF, rats were treated systemically with ANA-12, previously characterized as a selective and CNS-penetrant antagonist of the BDNF receptor TrkB. 17 Rats were given i.p. injections of ANA-12 (0.5 mg/kg) 24 hours after IL-6 administration on the dura (Fig. 4) . Systemic administration of ANA-12 blocked both the facial and hind paw response to dural pH 7.0 at the 72-hour time point. These data implicate BDNF in the development and/or maintenance of the primed state but do not provide information regarding the location of BDNF signaling necessary for priming.
To test whether BDNF signaling at central terminals of dural afferents in the TNC contributes to priming in this headache behavioral model, the BDNF sequestering agent TrkB-Fc was given through intracisternal injection to decrease extracellular levels of BDNF in the TNC. When TrkB-Fc was given 24 hours after dural IL-6, rats did not respond to dural pH 7.0 at the 72-hour time point (Fig. 5) . Animals treated with i.c. vehicle after IL-6 displayed allodynia 3 hours after dural pH 7.0 administration, similar to data shown in Figure 2 . This effect occurred regardless of the sex of the animal as both males and females were tested. These data demonstrate a role for central BDNF release in the maintenance of the primed state. If central BDNF is released after dural IL-6, and BDNF release contributes to the sensitivity to subsequent exposure to dural pH 7.0, then direct central administration of BDNF should recapitulate some or all the features present in the primed state. As shown in Figure 6 , i.c. administration of 1 or 10 pg of BDNF produced cutaneous facial allodynia that in the case of 1 pg is resolved by 72 hours. Because 1 pg i.c. BDNF produced a time course of allodynia similar to dural IL-6, this dose was chosen for future studies.
To determine whether i.c. administration of BDNF is capable of producing priming in the absence of dural stimulation, pH 7.0 was applied to the dura at the 72-hour time point after i.c. BDNF (1 pg). In animals treated with i.c. BDNF, pH 7.0 application to the dura 72 hours later produced facial allodynia, whereas dural vehicle given to i.c. BDNF animals produced no response at this time point (Fig. 7) . Prior administration of i.c. vehicle did not prime rats as neither pH 7.0 nor vehicle on the dura produced allodynia at 72 hours. Additionally, i.c. BDNF-treated animals were tested for responses to systemic NO donor administration after resolution of allodynia due to BDNF (Fig. 8) . At the 72-hour time point after i.c. BDNF, only BDNF-treated rats developed facial allodynia when given i.p SNP. Transient allodynia was observed in i.c. BDNF animals given vehicle at 72 hours but i.c. vehicle-treated animals did not respond to later administration of SNP or vehicle. To examine whether BDNF priming lasts beyond the 72-hour time point, animals were given i.c. BDNF or vehicle followed by systemic (i.p.) SNP at day 16 after BDNF (Fig. 8) . The BDNFtreated rats developed allodynia to SNP at this late time point, whereas there was no response to vehicle in these rats, indicating that BDNF priming lasts for weeks. Together, these data show that similar to stimulation of the dura with IL-6, direct central administration of BDNF is capable of producing priming to subsequent subthreshold stimuli including common migraine triggers.
Finally, to investigate whether priming to pH 7.0 application after IL-6 is unique to the dura or whether this is a generalizable effect in any part of the body, we gave IL-6 subcutaneously into the rat hind paw and tested for priming 72 hours later. Hind paw injection of IL-6 caused significant paw allodynia at 3 hours after injection (Fig. 9) . However, at 72 hours after IL-6, animals were not sensitized to pH 7.0 administered into the hind paw. These data demonstrate that although IL-6 is capable of priming other parts of the body to subthreshold stimulation, there may be unique mechanisms occurring within the dura and trigeminal afferent system that enable priming to specific stimuli.
Discussion
Migraine is most commonly an episodic disorder where, between attacks, patients are otherwise normal. However, during interictal periods, migraine patients likely carry underlying neuroplasticity that causes susceptibility to mild triggering events. The findings from these studies show that afferent input from the meninges, such as during the headache phase of migraine, can prime the nociceptive system to future subthreshold stimuli. Importantly, this primed state is present in rats that display no outward signs of hypersensitivity (eg, no cutaneous allodynia). Despite an otherwise normal phenotype, exposure to stimuli such as moderate changes in dural pH or systemic delivery of subthreshold doses of NO donors can provoke headache-related behavior. These studies also show that this primed state is dependent on central BDNF within the brainstem. Although migraine is a complex neurological disorder, the findings presented here implicate BDNF-dependent mechanisms as a contributing factor to the sensitivity to events and stimuli that are subthreshold in nonmigraineurs.
The presence of a primed state in otherwise normal rats where typically subthreshold events cause headache-related behaviors (cutaneous allodynia) mimics the phenotype of common episodic migraine. Given the presence of allodynia in other primary headache disorders, these data may also have implications for conditions such as cluster and tension-type headache. 2, 8 Our findings show that the primed state can develop after a single exposure of the dura to IL-6 or a single injection of i.c. BDNF. This suggests that a primed state in episodic migraine patients may be present after a minimal number of previous events. Although previous studies have shown that animals transition into a state of persistent allodynia after repetitive exposure to dural inflammatory mediators, 36 triptans, 20 or NO donors, 41 these models more closely mimic chronic migraine where headaches and allodynia are present most of the time. 29 Our study demonstrates that the neuroplasticity contributing to these chronic states may develop early and with repetitive exposure, may facilitate the transition from episodic to chronic migraine. Identification of plasticity mechanisms present during the episodic phase may allow these mechanisms to be targeted early, before the disorder progresses to a chronic state.
These studies demonstrate a role for central BDNF in priming of the dural afferent system, consistent with a pain-promoting role for this neuropeptide. 49 First, we show that the maintenance of priming requires BDNF signaling because priming was not present in IL-6-treated rats that were given the TrkB antagonist, ANA-12, 24 hours after IL-6. Second, the maintenance of priming requires central BDNF because sequestration of BDNF through i.c. injection of TrkB-Fc 24 hours after dural IL-6 can reverse the primed state. Third, we show that direct central administration of BDNF can both produce cutaneous allodynia and induce priming after resolution of allodynia. These actions of BDNF are consistent with a similar role for this neuropeptide in priming in the spinal system 32 and imply that BDNF may play a similar role in priming throughout the pain system. Our findings suggest that input from the meninges promotes the release of BDNF, contributing to neuroplasticity that underlies the primed state. Other studies have shown that dural stimulation leads to sensitization within the TNC (eg, see Refs. 4, 16), and our current data suggest that BDNF may play a role in these findings. Additionally, BDNF signaling may contribute to the sensitized state in models of chronic migraine (eg, because of repeated dural inflammatory mediators or triptan/ NO donor administration). Repetitive dural stimulation with inflammatory mediators was shown to both sensitize TNC neurons and to impair diffuse noxious inhibitory control (DNIC, a form of central descending modulation) in the TNC. 13 Chronic morphine administration also sensitized dural input into the TNC and impaired DNIC. 34 Although BDNF was not examined in these DNIC studies, chronic morphine exposure is known to increase spinal BDNF 24 providing a possible mechanistic link between BDNF and the loss of TNC DNIC. Our current work suggests that BDNF may be a unifying factor in the generation of plasticity in the TNC that contributes to migraine and other forms of primary headache.
An important observation from these studies is that central administration of BDNF, without any previous dural stimulation, promotes headache-like behavior after subsequent stimulation of the dura with pH 7.0. Dural stimulation with IL-6 produced similar priming to pH 7.0, and while we have shown previously that IL-6 can sensitize dural afferents, 57 central BDNF administration is not likely to sensitize nerve endings in the dura mater. Thus, this central mechanism can exist independent of any hypersensitivity present in peripheral terminals before or during headache. Central sensitization in the TNC may enhance transmission of background levels of input from the meninges. Additionally, hypersensitivity in dural nerve endings would likely further enhance afferent trafficking. A variety of activating/sensitizing mechanisms within the dura have been proposed to contribute to migraine, 7, 15 and these may occur in addition to central sensitization creating efficient afferent signaling in response to otherwise nonnoxious events.
Interleukin-6 injection into the hind paw or gastrocnemius muscle causes priming to later injections of prostaglandin E 2 that is also dependent on central BDNF. 21, 32 These studies suggest that BDNF-dependent IL-6 priming is not unique to migraine but may exist throughout the pain system. However, specific mechanistic differences may also exist depending on location, priming stimulus, and what stimuli animals become primed to. We show here that while dural IL-6 causes priming to later injection of a pH 7.0 solution, the same is not true in the hind paw as rats did not respond to pH 7.0 after injection of the same dose of IL-6 into the paw. We have shown previously that dural afferents are sensitive to subtle changes in pH 56, 58 so this stimulus may be particularly important in the dura and not in the paw skin. Thus, while priming may be common in the pain system, nociceptive pathways may ultimately become more effectively primed to stimuli that are most important in the local environment.
The BDNF can be released from both primary afferents 28, 33, 59 and microglia. 5 Calcitonin gene-related peptide, which is closely linked to migraine, 10, 44 promotes the release of BDNF from trigeminal neurons 14 and this may be one downstream mechanism by which administration of calcitonin gene-related peptide triggers migraine. Levels of serum BDNF are elevated in migraine patients during attacks compared with between attacks 25, 52 (although see Ref. 11) , further implicating BDNF in migraine in humans. However, recent work in several mouse pain models found that release of BDNF from spinal microglia does not contribute to pain in female mice. 50 Our data show that sequestration of central BDNF reverses priming in both males and females. This may indicate that the source of BDNF in this primed state is not microglia but that BDNF released from afferents contributes to priming. Future work is necessary to identify the source of BDNF for priming, potentially using tools Asterisks are used to summarize significance based on P value. P values are summarized as follows; *P # 0.05, **P # 0.01, ***P # 0.001, and ****P # 0.0001. Figure 9 . Hind paw application of interleukin-6 (IL-6) fails to prime animals to subthreshold pH stimulation of the hind paw. Animals received application of IL-6 in the hind paw and show paw allodynia. Animals do not exhibit cutaneous allodynia when pH 7.0 is applied to the hind paw (n 5 5 for all groups) after the resolution of IL-6 allodynia at 72 hours. Two-factor analysis of variance indicated a significant effect of both treatment and time of the hind paws. Significant differences among mean values for each group were determined by analysis of variance followed by Bonferroni post hoc test. Hind paw: time F (9,90) 5 4.11, P 5 0.0002, treatment F (1,90) 5 20.47, P , 0.0001. ****P # 0.0001. such as mice where BDNF is deleted from primary afferents 59 or deleted from microglia. 37 Although our findings suggest that targeting BDNF/TrkB may have potential for the treatment of migraine, BDNF is thought to contribute to a variety of beneficial neurological processes and decreased BDNF may contribute to several disorders. Among these are learning/memory, major depressive disorder, anxiety, and addiction. 3, 6, 27 Thus, a more likely therapeutic strategy will be to identify downstream mechanisms by which BDNF and TrkB signaling contribute to priming of the dural nociceptive system. The BDNF increases excitability and signaling of pain pathways through altered Cl 2 gradients, increased glutamate (AMPA/NMDA), ASIC1a, and voltage-gated Na 1 currents 12, 49 and can regulate the synthesis and activity of atypical protein kinase C. 32 In the trigeminal system, BDNF application increased expression of the ATP-gated ion channel P2X3 48 and decreased voltage-gated K 1 currents in neurons projecting to the nucleus interpolaris/caudalis transition zone, 51 a region known to contribute to the development of persistent orofacial pain. 43 Activation of protein kinase Cg-expressing interneurons in the medullary dorsal horn also contributes to pain states in the trigeminal system, 40 and this mechanism may be engaged downstream of BDNF/TrkB signaling. The above mechanisms may contribute to the primed state and it will be important to identify BDNF mechanisms that are unique to nociceptive priming that could be exploited for novel migraine therapeutics.
Together, these studies indicate that afferent input from the meninges, which occurs during headache, primes the dural nociceptive system using central release of BDNF. This suggests that headache events themselves contribute to future headaches. Our data demonstrate that a single round of either meningeal input or BDNF intracisternally can induce neuroplasticity leading to priming. Although other preclinical migraine models use repetitive stimulation to produce sensitization, 20, 36, 41 BDNF in the TNC may provide a common link between these models as it is a critical mediator of plasticity related to pain. 49 Assessment of a role for BDNF in the variety of stimuli that contribute to migraine, and identification of downstream events after activation of TrkB, could lead to novel therapeutics targeting the neuroplasticity present in migraine patients.
